Related Experiment Video
Updated: Jun 12, 2025
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Improving Outcomes for Women With Metastatic HER2-Positive and HER2-Low Breast Cancer
Stephanie L Graff1,2, Christine McGinn1, Jeanine R Showalter1
1From Lifespan Cancer Institute, Providence, Rhode Island.
Abstract:
At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status, and evidence-based practices for managing adverse events associated with novel HER2 agents.
Insights
JADPRO Live 2023 highlighted updates in HER2-positive metastatic breast cancer clinical practice. Key topics included new FDA approvals, the significance of HER2-low status, and managing side effects from new HER2-targeted therapies.
Area of Science:
- Oncology
- Clinical Practice
- Pharmacology
Background:
- Metastatic HER2-positive breast cancer requires ongoing treatment advancements.
- Recent developments necessitate updates in clinical management strategies.
Purpose of the Study:
- To summarize key discussions from JADPRO Live 2023 on metastatic HER2-positive breast cancer.
- To highlight recent FDA approvals and their clinical implications.
- To discuss the evolving understanding and management of HER2-low breast cancer.
Main Methods:
- Review of presentations and discussions from JADPRO Live 2023.
- Analysis of recent FDA approvals relevant to HER2-positive breast cancer.
- Examination of evidence-based practices for managing adverse events.
Main Results:
- Recent FDA approvals offer new therapeutic options for HER2-positive metastatic breast cancer.
- The clinical relevance of HER2-low status is increasingly recognized.
- Effective strategies for managing adverse events associated with novel HER2 agents were presented.
Conclusions:
- Continuous education on new approvals and treatment paradigms is crucial.
- Understanding HER2-low status is vital for personalized treatment approaches.
- Proactive management of adverse events ensures optimal patient outcomes with novel HER2 therapies.
